Abstract
Cells in the stromal microenvironment facilitate colorectal cancer (CRC) progression and “co-evolve” with the epithelial cancer cells. Genetic and epigenetic differences between normal colorectal mucosa fibroblasts (NF) and carcinoma- associated fibroblasts (CAF) are not known. The aim of this study is to identify differentially expressed genes and promoter methylation between NF and CAF in human CRC. RNA and DNA were extracted from cultured NF and CAF from CRC resections. Genome-wide gene expression and methylation analyses were performed using the Illumina Human HT-12 v4.0 Expression and Illumina Human Methylation27 BeadChips. Gene expression values between NF and CAF were compared and correlated with methylation patterns. Data was analyzed with Partek Genomics Suite using one-way ANOVA and p<0.05 as significant. Ingenuity iReportTM was performed to identify potential differences in biological functions and pathways between the NF and CAF. Paired methylation and gene expression analyses from 11 NF and 10 CAF colorectal samples are reported. Unsupervised analysis of differentially expressed genes using iReportTM identified “Top Diseases” as “Cancer” and “Colorectal Cancer”. Previous genome wide studies have focused on the cancer cells. We have identified differentially expressed genes and differentially methylated promoter regions that are CAF-specific in CRC.
Keywords: Carcinoma-associated fibroblasts, colorectal cancer, gene expression, normal colorectal mucosal fibroblasts, microarray, promoter methylation.
Current Cancer Therapy Reviews
Title:Colorectal Cancer-Associated Fibroblasts are Genotypically Distinct
Volume: 10 Issue: 2
Author(s): Amy A. Mrazek, Joseph R. Carmical, Thomas G. Wood, Mark R. Hellmich, Mahmoud Eltorky and Celia Chao
Affiliation:
Keywords: Carcinoma-associated fibroblasts, colorectal cancer, gene expression, normal colorectal mucosal fibroblasts, microarray, promoter methylation.
Abstract: Cells in the stromal microenvironment facilitate colorectal cancer (CRC) progression and “co-evolve” with the epithelial cancer cells. Genetic and epigenetic differences between normal colorectal mucosa fibroblasts (NF) and carcinoma- associated fibroblasts (CAF) are not known. The aim of this study is to identify differentially expressed genes and promoter methylation between NF and CAF in human CRC. RNA and DNA were extracted from cultured NF and CAF from CRC resections. Genome-wide gene expression and methylation analyses were performed using the Illumina Human HT-12 v4.0 Expression and Illumina Human Methylation27 BeadChips. Gene expression values between NF and CAF were compared and correlated with methylation patterns. Data was analyzed with Partek Genomics Suite using one-way ANOVA and p<0.05 as significant. Ingenuity iReportTM was performed to identify potential differences in biological functions and pathways between the NF and CAF. Paired methylation and gene expression analyses from 11 NF and 10 CAF colorectal samples are reported. Unsupervised analysis of differentially expressed genes using iReportTM identified “Top Diseases” as “Cancer” and “Colorectal Cancer”. Previous genome wide studies have focused on the cancer cells. We have identified differentially expressed genes and differentially methylated promoter regions that are CAF-specific in CRC.
Export Options
About this article
Cite this article as:
Mrazek A. Amy, Carmical R. Joseph, Wood G. Thomas, Hellmich R. Mark, Eltorky Mahmoud and Chao Celia, Colorectal Cancer-Associated Fibroblasts are Genotypically Distinct, Current Cancer Therapy Reviews 2014; 10 (2) . https://dx.doi.org/10.2174/157339471002141124123103
DOI https://dx.doi.org/10.2174/157339471002141124123103 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Immunological Function of iGb3
Current Protein & Peptide Science Green Tea Catechins as Novel Antitumor and Antiangiogenic Compounds
Current Medicinal Chemistry - Anti-Cancer Agents Artificial O2 Carriers: Status in 2005
Current Pharmaceutical Design Systemic Delivery of Curcumin: 21st Century Solutions for an Ancient Conundrum
Current Drug Discovery Technologies Power from the Garden: Plant Compounds as Inhibitors of the Hallmarks of Cancer
Current Medicinal Chemistry Cancer Bioinformatics for Updating Anticancer Drug Developments and Personalized Therapeutics
Reviews on Recent Clinical Trials Histone Deacetylases as Targets for Dietary Cancer Preventive Agents: Lessons Learned with Butyrate, Diallyl Disulfide, and Sulforaphane
Current Drug Targets Ras-Induced Resistance to Lapatinib is Overcome by MEK Inhibition
Current Cancer Drug Targets Targeted Drug Delivery System for Platinum-based Anticancer Drugs
Mini-Reviews in Medicinal Chemistry A Review on Exploring Better Safety Prospects in Managing Cancer using Liposomal Combinations of Food Bioactive Compounds and Anticancer Drugs: Combisomes
Current Drug Delivery Recent Advances in Herbal Nanomedicines for Cancer Treatment
Current Molecular Pharmacology Anticancer Drug Combinations, How Far We can Go Through?
Anti-Cancer Agents in Medicinal Chemistry The Function of LncRNA FTX in Several Common Cancers
Current Pharmaceutical Design Post-Transcriptional and Post-translational Regulation of Central Carbon Metabolic Enzymes in Cancer
Anti-Cancer Agents in Medicinal Chemistry Flavonoids and other Non-alkaloidal Constituents of Genus Erythrina: Phytochemical Review
Combinatorial Chemistry & High Throughput Screening Epidermal Growth Factor Receptor-Targeted Therapy of Colorectal Cancer with Panitumumab
Current Cancer Therapy Reviews Antineoplastic Activity, Structural Modification, Synthesis and Structure-activity Relationship of Dammarane-type Ginsenosides: An Overview
Current Organic Chemistry Exosomes and Lung Cancer: Roles in Pathophysiology, Diagnosis and Therapeutic Applications
Current Medicinal Chemistry Presenilin and γ -Secretase Activity: A Viable Therapeutic Target for Alzheimers Disease?
Current Signal Transduction Therapy Remodelling of the Ca2+ Toolkit in Tumor Endothelium as a Crucial Responsible for the Resistance to Anticancer Therapies
Current Signal Transduction Therapy